<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077749</url>
  </required_header>
  <id_info>
    <org_study_id>2017-041</org_study_id>
    <nct_id>NCT04077749</nct_id>
  </id_info>
  <brief_title>Probiotic Bladder Instillation for Prevention of Catheter Associated UTIs in Chronically Catheterized Patients</brief_title>
  <official_title>A Randomized Double Blinded Study of Probiotic Bladder Instillation for Prevention of Catheter Associated UTIs in Chronically Catheterized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lahey Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a randomized, placebo-controlled clinical trial to test the efficacy of
      an oral Lactobacillus product dissolved in sterile saline and instilled into the urinary
      bladder in an attempt to colonize the urinary bladder as well as prevent UTIs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who use a chronic indwelling urinary catheter to drain their bladder will be
      randomized to receive intravesical instillations of a Lactobacillus solution or sterile
      saline at the time of a scheduled monthly catheter exchange. Bacterial colonization and
      frequency of urinary tract infections will be compared between the two groups.

      The Lactobacillus solution will be derived from the combination of Lactobacillus rhamnosus
      (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic
      capsule sold under the brand name of Femdophilus and manufactured by CHR-Hansen of Denmark
      (phone: +45 45747474; email: info@chr-hansen.com). The contents of the capsules will be
      dissolved in 50 mL of normal saline at room temperature within one hour prior to
      administration and left indwelling in the patient's urinary bladder for 30 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bladder colonization with Lactobacillus</measure>
    <time_frame>6 months</time_frame>
    <description>Percent of patients with urine cultures positive for lactobacilli species after 6 months.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Femdophilus probiotic</intervention_name>
    <description>Lactobacillus rhamnosus (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic capsule sold under the brand name of Femdophilus dissolved in 50 mL normal saline at room temperature.</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>50 mL normal saline at room temperature</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 years of age

          2. Chronic indwelling urethral catheter or supra-pubic tube for &gt;6 months

          3. Prior symptomatic UTI while catheter in place

        Exclusion Criteria:

          1. Immunosuppressed (HIV, transplant immunosuppression, uncontrolled diabetes)

          2. Active infection (may be considered after treatment of active infection)

          3. Prior urosepsis requiring ICU admission

          4. Significant gross hematuria resulting from catheter exchanges

          5. Supravesical urinary diversion

          6. Upper urinary tract anatomical abnormality

          7. Obstructing urolithiasis

          8. Ongoing antibiotic therapy for non-urological infection

          9. Indwelling nephrostomy tube or ureteral stent

         10. Radiation cystitis

         11. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Harjivan S Kohli, MD</last_name>
    <phone>7815049386</phone>
    <email>harjivan.kohli@lahey.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lara Maclachlan, MD</last_name>
    <email>lara.maclachlan@lahey.org</email>
  </overall_contact_backup>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

